CCL2 and breast carcinoma: Although inhibition of monocyte mobilization remains therapeutically promising, a recent study by Bonapace et al. 124 found that cessation of antibody-mediated CCL2-blockade during murine models of breast cancer resulted in a rapid and profound increase in pulmonary metastasis and accelerated death.